This Article Full Text Full Text (PDF) All Versions of this Article: 107/19/2403    most recent 01.CIR.0000072764.18315.6Bv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sinha, M. K. Articles by Kaski, J. C. Search for Related Content PubMed PubMed Citation Articles by Sinha, M. K. Articles by Kaski, J. C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Angioplasty Hazardous Substances DB PROSTAGLANDIN F2ALPHA Related Collections Other diagnostic testing

(Circulation. 2003;107:2403.)
© 2003 American Heart Association, Inc.

Brief Rapid Communications

Ischemia Modified Albumin Is a Sensitive Marker of Myocardial Ischemia After Percutaneous Coronary Intervention

Manas K. Sinha, MRCP; David C. Gaze, BSc; John R. Tippins, PhD; Paul O. Collinson, FRCPath; Juan Carlos Kaski, MD, DSc, FRCP, FESC

From the Coronary Artery Disease Research Unit (M.K.S., J.C.K.), and Chemical Pathology (D.C.G., P.O.C.), St George’s Hospital, London, UK; and the Department of Biological Sciences (J.R.T.), Imperial College of Science, Technology and Medicine, London, UK.

Correspondence to Prof Juan Carlos Kaski, Coronary Artery Disease Research Unit, Cardiological Sciences, St George’s Hospital Medical School, Cranmer Terrace, London SW17 0RE. E-mail jkaski{at}sghms.ac.uk

Background— Ischemia modified albumin (IMA; Ischemia Technologies, Inc) blood levels rise in patients who develop ischemia during percutaneous coronary intervention (PCI). It is not known whether IMA elevations correlate with increases in other markers of oxidative stress, ie, 8-iso prostaglandin F2-A (iP).

Methods and Results— We compared IMA versus iP plasma levels in 19 patients (mean age 62.8±11.9 years) undergoing PCI and 11 patients (mean age 64±13.6 years) undergoing diagnostic angiography (controls). In the PCI patients, blood samples for IMA and iP were taken from the guide catheter before PCI and after balloon inflations, and from the femoral sheath 30 minutes after PCI. IMA was measured by the albumin cobalt binding (ACB) test and plasma iP by enzyme immunoassay. During PCI, all 19 patients had chest pain and 18 had transient ischemic ST segment changes. IMA was elevated from baseline in 18 of the 19 patients after PCI. Median IMA levels were higher after PCI (101.4 U/mL, 95%CI 82 to 116) compared with baseline (72.8 U/mL, CI 55 to 93; P<0.0001). Levels remained elevated at 30 minutes (87.9 U/mL, CI 78 to 99; P<0.0001) and returned to baseline at 12 hours (70.3 U/mL, CI 65 to 87; P=0.65). iP levels were raised after PCI in 9 of the 19 patients. However, median iP levels were not significantly different immediately (P=0.6) or 30 minutes after PCI (P=0.1). In the control group, IMA and iP levels remained unchanged before and after angiography (P=0.2 and 0.16, respectively).

Conclusions— IMA is a more consistent marker of ischemia than iP in patients who develop chest pain and ST segment changes during PCI.

Key Words: ischemia • proteins • angioplasty

This article has been cited by other articles:

				H Demir, B C Topkaya, A R Erbay, M Dogan, and D Yucel Ischaemia-modified albumin elevation after percutaneous coronary intervention reflects albumin concentration rather than ischaemia Ann Clin Biochem, July 1, 2009; 46(4): 327 - 331. [Abstract] [Full Text] [PDF]

				E. Sbarouni, P. Georgiadou, M. Koutelou, I. Sklavainas, D. Panagiotakos, and V. Voudris Ischaemia-modified albumin in dilated cardiomyopathy Ann Clin Biochem, May 1, 2009; 46(3): 241 - 243. [Abstract] [Full Text] [PDF]

				S. S. Talwalkar, M. Bon-Homme, J. J. Miller, and R. J. Elin Ischemia Modified Albumin, a Marker of Acute Ischemic Events: A Pilot Study Ann. Clin. Lab. Sci., January 1, 2008; 38(2): 132 - 137. [Abstract] [Full Text] [PDF]

				N. Morikawa, Y. Kawai, K. Arakawa, T. Kumamoto, I. Miyamori, H. Akao, M. Kitayama, K. Kajinami, J.-D. Lee, H. Takeshita, et al. Serum deoxyribonuclease I activity can be used as a novel marker of transient myocardial ischaemia: results in vasospastic angina pectoris induced by provocation test Eur. Heart J., December 2, 2007; 28(24): 2992 - 2997. [Abstract] [Full Text] [PDF]

				D. Roy and J. C. Kaski High-risk acute coronary syndrome patients and cardiac biomarkers in the emergency department: any role for new biomarkers of myocardial ischaemia? Eur. Heart J., September 2, 2007; 28(18): 2297 - 2297. [Full Text] [PDF]

				D. Roy and J. C. Kaski IMA the role of oxidative stress Europace, September 1, 2007; 9(9): 854 - 854. [Full Text] [PDF]

				E. Sbarouni IMA the role of oxidative stress: reply Europace, September 1, 2007; 9(9): 854 - 855. [Full Text] [PDF]

				D. Roy and J. C. Kaski Ischemia-Modified Albumin: The Importance of Oxidative Stress J. Am. Coll. Cardiol., June 19, 2007; 49(24): 2375 - 2376. [Full Text] [PDF]

				M K Sinha, J M Vazquez, R Calvino, D C Gaze, P O Collinson, and J C Kaski Effects of balloon occlusion during percutaneous coronary intervention on circulating Ischemia Modified Albumin and transmyocardial lactate extraction Heart, December 1, 2006; 92(12): 1852 - 1853. [Full Text] [PDF]

				N. Middleton, R. Shave, K. George, G. Whyte, J. Forster, D. Oxborough, D. Gaze, and P. Collinson Novel application of flow propagation velocity and ischaemia-modified albumin in analysis of postexercise cardiac function in man Exp Physiol, May 1, 2006; 91(3): 511 - 519. [Abstract] [Full Text] [PDF]

				P O Collinson, D C Gaze, K Bainbridge, F Morris, B Morris, A Price, and S Goodacre Utility of admission cardiac troponin and "Ischemia Modified Albumin" measurements for rapid evaluation and rule out of suspected acute myocardial infarction in the emergency department. Emerg. Med. J., April 1, 2006; 23(4): 256 - 261. [Abstract] [Full Text] [PDF]

				M. K. Sinha, D. Roy, and J. C. Kaski Markers of myocardial ischaemia Eur. Heart J., March 2, 2006; 27(6): 758 - 758. [Full Text] [PDF]

				D Roy, J Quiles, D C Gaze, P Collinson, J C Kaski, and G F Baxter Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin Heart, January 1, 2006; 92(1): 113 - 114. [Full Text] [PDF]

				J. Herrmann Peri-procedural myocardial injury: 2005 update Eur. Heart J., December 1, 2005; 26(23): 2493 - 2519. [Abstract] [Full Text] [PDF]

				R. H. Christenson, C. P. deFilippi, and D. Kreutzer Biomarkers of Ischemia in Patients With Known Coronary Artery Disease: Do Interleukin-6 and Tissue Factor Measurements During Dobutamine Stress Echocardiography Give Additional Insight? Circulation, November 22, 2005; 112(21): 3215 - 3217. [Full Text] [PDF]

				K. Arakawa, Y. Kawai, T. Kumamoto, N. Morikawa, M. Yoshida, H. Tada, R. Kawaguchi, K. Taniguchi, I. Miyamori, Y. Kominato, et al. Serum deoxyribonuclease I activity can be used as a sensitive marker for detection of transient myocardial ischaemia induced by percutaneous coronary intervention Eur. Heart J., November 2, 2005; 26(22): 2375 - 2380. [Abstract] [Full Text] [PDF]

				M. Thielmann, P. Massoudy, A. Schmermund, M. Neuhauser, G. Marggraf, M. Kamler, U. Herold, I. Aleksic, K. Mann, M. Haude, et al. Diagnostic discrimination between graft-related and non-graft-related perioperative myocardial infarction with cardiac troponin I after coronary artery bypass surgery Eur. Heart J., November 2, 2005; 26(22): 2440 - 2447. [Abstract] [Full Text] [PDF]

				R. Bito, S. Hino, A. Baba, M. Tanaka, H. Watabe, and H. Kawabata Degradation of oxidative stress-induced denatured albumin in rat liver endothelial cells Am J Physiol Cell Physiol, September 1, 2005; 289(3): C531 - C542. [Abstract] [Full Text] [PDF]

				A. Worster, P.J. Devereaux, D. Heels-Ansdell, G. H. Guyatt, J. Opie, F. Mookadam, and S. A. Hill Capability of ischemia-modified albumin to predict serious cardiac outcomes in the short term among patients with potential acute coronary syndrome Can. Med. Assoc. J., June 21, 2005; 172(13): 1685 - 1690. [Abstract] [Full Text] [PDF]

				M. S. Sabatine When prognosis precedes diagnosis: putting the cart before the horse Can. Med. Assoc. J., June 21, 2005; 172(13): 1697 - 1698. [Full Text] [PDF]

				F. S. Apple, A. H.B. Wu, J. Mair, J. Ravkilde, M. Panteghini, J. Tate, F. Pagani, R. H. Christenson, M. Mockel, O. Danne, et al. Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome Clin. Chem., May 1, 2005; 51(5): 810 - 824. [Abstract] [Full Text] [PDF]

				D. Roy, J. Quiles, R. Sharma, M. Sinha, P. Avanzas, D. Gaze, and J. C. Kaski Ischemia-Modified Albumin Concentrations in Patients with Peripheral Vascular Disease and Exercise-Induced Skeletal Muscle Ischemia Clin. Chem., September 1, 2004; 50(9): 1656 - 1660. [Abstract] [Full Text] [PDF]

				M. Panteghini Role and importance of biochemical markers in clinical cardiology Eur. Heart J., July 2, 2004; 25(14): 1187 - 1196. [Abstract] [Full Text] [PDF]

				M. Kemp, J. Donovan, H. Higham, and J. Hooper Biochemical markers of myocardial injury Br. J. Anaesth., July 1, 2004; 93(1): 63 - 73. [Abstract] [Full Text] [PDF]

				E. Zapico-Muniz, M. Santalo-Bel, J. Merce-Muntanola, J. A. Montiel, A. Martinez-Rubio, and J. Ordonez-Llanos Ischemia-Modified Albumin during Skeletal Muscle Ischemia Clin. Chem., June 1, 2004; 50(6): 1063 - 1065. [Full Text] [PDF]

				M K Sinha, D Roy, D C Gaze, P O Collinson, and J-C Kaski Role of "Ischemia Modified Albumin", a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes Emerg. Med. J., January 1, 2004; 21(1): 29 - 34. [Abstract] [Full Text] [PDF]